^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Herceptin (trastuzumab)

    i
    Company:
    Roche
    Drug class:
    HER2 inhibitor
    Related drugs:
    Apply
    Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (NCT05063786)
    Phase 3
    Spanish Breast Cancer Research Group
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/14/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    HER-2 • ER • PIK3CA • PGR
    |
    ER positive • PIK3CA mutation
    |
    Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer (NRG-GY026) (NCT05256225)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/16/2022
    Primary completion :
    10/31/2027
    Completion :
    10/31/2027
    HER-2 • TP53
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects (FLAMINGO-01) (NCT05232916)
    Phase 3
    Greenwich LifeSciences, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/11/2022
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    HER-2 • HLA-A
    |
    HLA-A*02 positive
    |
    Herceptin (trastuzumab) • GLSI-100 • GP2
    A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) (NCT05253651)
    Phase 3
    Seagen Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/24/2022
    Primary completion :
    04/03/2026
    Completion :
    07/27/2029
    HER-2
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium • levoleucovorin calcium
    Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (NCT04886531)
    Phase 2
    Ruth O'Regan
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/21/2022
    Primary completion :
    09/01/2025
    Completion :
    10/01/2025
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole
    Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT05730712)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/08/2024
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    NRG1
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Xtandi (enzalutamide) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) (NCT04721977)
    Phase 2
    Pfizer
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    04/08/2021
    Primary completion :
    07/17/2023
    Completion :
    11/25/2025
    HER-2
    |
    Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01) (NCT05152147)
    Phase 3
    Jazz Pharmaceuticals
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/02/2021
    Primary completion :
    05/15/2025
    Completion :
    05/15/2026
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)
    Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer (NCT01093612)
    Phase N/A
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    03/16/2011
    Primary completion :
    10/23/2018
    Completion :
    08/26/2025
    HER-2
    |
    HER-2 negative
    |
    Herceptin (trastuzumab)
    An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis (NCT05376878)
    Phase 4
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    12/21/2022
    Primary completion :
    02/25/2026
    Completion :
    02/25/2026
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trazimera (trastuzumab-qyyp)
    Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer (NCT02226276)
    Phase N/A
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    01/07/2015
    Primary completion :
    12/07/2021
    Completion :
    10/30/2025
    HER-2
    |
    HER-2 positive • HER-2 positive + HER-2 overexpression
    |
    Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine)
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (MORPHEUS BC) (NCT04802759)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/22/2021
    Primary completion :
    11/30/2027
    Completion :
    11/30/2027
    ER • CDK4
    |
    HER-2 positive • ER positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (GDC-9545) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)
    A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants with Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer) (NCT05415215)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/05/2022
    Primary completion :
    11/20/2024
    Completion :
    12/31/2025
    HER-2
    |
    HER-2 amplification • EGFR positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa) (NCT05306041)
    Phase 2
    German Breast Group
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/02/2023
    Primary completion :
    10/01/2026
    Completion :
    01/01/2027
    HER-2 • PIK3CA • PGR
    |
    HER-2 positive • PIK3CA mutation • PGR positive
    |
    Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer (NCT06123338)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    02/01/2024
    Primary completion :
    11/30/2027
    Completion :
    11/30/2027
    HER-2
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • oxaliplatin
    Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer (BOLD-1) (NCT02625441)
    Phase 3
    Helsinki University Central Hospital
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    12/01/2015
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab)
    Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. (NCT01649271)
    Phase 1
    Boehringer Ingelheim
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    07/23/2012
    Primary completion :
    06/23/2016
    Completion :
    06/23/2016
    HER-2
    |
    HER-2 overexpression
    |
    Herceptin (trastuzumab) • Gilotrif (afatinib)
    Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer. (NCT00950742)
    Phase 1
    Boehringer Ingelheim
    Completed
    Last update posted :
    02/10/2025
    Initiation :
    08/01/2009
    Primary completion :
    10/01/2013
    Completion :
    10/01/2013
    HER-2
    |
    HER-2 amplification
    |
    Herceptin (trastuzumab) • Gilotrif (afatinib)
    Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (NCT04379596)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    06/03/2020
    Primary completion :
    07/30/2026
    Completion :
    07/30/2026
    HER-2
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy (NCT00769379)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/10/2008
    Primary completion :
    12/31/2019
    Completion :
    03/07/2025
    HER-2 • PGR
    |
    HER-2 positive • HR positive
    |
    Herceptin (trastuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab)
    Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery (CALGB-40601) (NCT00770809)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/01/2008
    Primary completion :
    01/31/2014
    Completion :
    07/10/2025
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • lapatinib • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)
    Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer (NCT04329065)
    Phase 2
    University of Washington
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    04/20/2022
    Primary completion :
    06/30/2025
    Completion :
    06/30/2027
    HER-2 • ER • PGR • CD4
    |
    ER negative • PGR negative
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)
    Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (SGNTUC 024) (NCT04430738)
    Phase 1/2
    Seagen Inc.
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    09/15/2020
    Primary completion :
    07/31/2024
    Completion :
    10/31/2025
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction (NCT04661150)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/12/2021
    Primary completion :
    05/08/2023
    Completion :
    06/30/2026
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • capecitabine • oxaliplatin
    Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (DESTINY-Breast11) (NCT05113251)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    10/25/2021
    Primary completion :
    03/12/2025
    Completion :
    04/30/2027
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • cyclophosphamide intravenous
    First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) (NCT05749900)
    Phase 1/2
    Yonsei University
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    05/12/2023
    Primary completion :
    02/28/2026
    Completion :
    02/28/2027
    HER-2
    |
    HER-2 positive
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • cisplatin • gemcitabine
    Tucatinib Together with Pembrolizumab and Trastuzumab (TUGETHER) (NCT04789096)
    Phase 2
    Breast Cancer Trials, Australia and New Zealand
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    03/07/2023
    Primary completion :
    09/30/2025
    Completion :
    09/01/2026
    HER-2 • PD-L1
    |
    PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib)
    Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer (TBCRC 050) (NCT03368729)
    Phase 1/2
    University of Alabama at Birmingham
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    09/06/2019
    Primary completion :
    11/01/2026
    Completion :
    12/30/2026
    PGR
    |
    PGR positive • EGFR positive
    |
    Herceptin (trastuzumab) • Zejula (niraparib)
    T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) (NCT01853748)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    05/01/2013
    Primary completion :
    08/26/2019
    Completion :
    12/01/2025
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • paclitaxel • Kadcyla (ado-trastuzumab emtansine)
    Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease (NCT04588545)
    Phase 1/2
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/10/2020
    Primary completion :
    07/29/2025
    Completion :
    07/29/2025
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer (met-HEReMYTA) (NCT02488564)
    Phase 2
    Istituto Scientifico Romagnolo per lo Studio e ...
    Completed
    Last update posted :
    02/03/2025
    Initiation :
    12/17/2014
    Primary completion :
    10/01/2018
    Completion :
    03/17/2020
    HER-2
    |
    HER-2 overexpression
    |
    Herceptin (trastuzumab) • docetaxel • metformin • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal
    Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD (CLIMB-LMD) (NCT06016387)
    Phase 2
    Sunnybrook Health Sciences Centre
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    11/25/2023
    Primary completion :
    10/05/2025
    Completion :
    10/05/2028
    HER-2
    |
    Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib)
    TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535)
    Phase 2
    American Society of Clinical Oncology
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/14/2016
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    BRAF
    |
    ER positive • HER-2 negative • PGR positive
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • Torisel (temsirolimus) • letrozole • Inlyta (axitinib) • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension
    Safety and Efficacy of Trastuzumab BS (NCT04181333)
    Phase N/A
    Pfizer
    Active, not recruiting
    Last update posted :
    01/28/2025
    Initiation :
    08/09/2023
    Primary completion :
    02/14/2025
    Completion :
    02/14/2025
    HER-2
    |
    HER-2 overexpression
    |
    Herceptin (trastuzumab) • Trazimera (trastuzumab-qyyp)
    Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer (NCI-2016-00570) (NCT02827877)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    07/15/2016
    Primary completion :
    07/02/2020
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 positive • HER-2 positive + HER-2 overexpression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Trazimera (trastuzumab-qyyp)
    Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101) (NCT06625775)
    Phase 1
    TheRas, Inc., d/b/a BridgeBio Oncology Therapeu...
    Recruiting
    Last update posted :
    01/24/2025
    Initiation :
    10/29/2024
    Primary completion :
    11/01/2028
    Completion :
    11/01/2028
    KRAS
    |
    Herceptin (trastuzumab)
    A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) (NCT04188548)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    01/22/2025
    Initiation :
    12/10/2019
    Primary completion :
    06/29/2020
    Completion :
    12/01/2027
    ER
    |
    HER-2 negative • EGFR positive
    |
    Herceptin (trastuzumab) • everolimus • Perjeta (pertuzumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • exemestane • Inluriyo (imlunestrant)
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (SWOG S1613) (NCT03365882)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    01/14/2025
    Initiation :
    11/27/2017
    Primary completion :
    11/01/2022
    Completion :
    11/30/2025
    HER-2 • KRAS • BRAF • NRAS
    |
    BRAF V600E • HER-2 amplification • BRAF V600
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • Perjeta (pertuzumab) • irinotecan • Trazimera (trastuzumab-qyyp)
    A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY) (NCT01358877)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    01/13/2025
    Initiation :
    11/08/2011
    Primary completion :
    12/19/2016
    Completion :
    11/28/2024
    HER-2 • ER • PGR
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • cyclophosphamide intravenous
    Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) (NCT02947685)
    Phase 3
    Alliance Foundation Trials, LLC.
    Active, not recruiting
    Last update posted :
    01/13/2025
    Initiation :
    06/21/2017
    Primary completion :
    10/15/2024
    Completion :
    07/31/2026
    PIK3CA • PGR
    |
    HER-2 positive • HR positive • PIK3CA mutation
    |
    Herceptin (trastuzumab) • Ibrance (palbociclib) • Perjeta (pertuzumab) • fulvestrant • letrozole • anastrozole • exemestane
    Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer (NCT03125928)
    Phase 2
    Fox Chase Cancer Center
    Active, not recruiting
    Last update posted :
    01/10/2025
    Initiation :
    06/13/2017
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • Perjeta (pertuzumab)